INVEGA SUSTENNA 50 mg Pre-filled syringe
INVEGA SUSTENNA 50 mg Pre-filled Syringe: Long-Acting Treatment for Schizophrenia and Schizoaffective Disorder
INVEGA SUSTENNA 50 mg Pre-filled Syringe is an advanced, long-acting injectable medication designed to manage the symptoms of schizophrenia and schizoaffective disorder in adults. This innovative treatment offers the convenience of once-monthly dosing after initial treatment, helping to improve medication adherence and maintain consistent therapeutic levels of the active ingredient, paliperidone palmitate. It provides a steady release of medication, which can lead to better symptom control and a reduced risk of relapse compared to daily oral antipsychotics. Developed by Janssen, INVEGA SUSTENNA is a critical tool in comprehensive mental health care plans.
Benefits of Use
- Provides sustained symptom control for schizophrenia and schizoaffective disorder.
- Once-monthly dosing improves medication adherence and reduces the burden of daily pill taking.
- Helps maintain consistent drug levels in the body, minimizing fluctuations in symptoms.
- Offers a discreet treatment option, supporting privacy for patients.
- Contributes to a reduced risk of relapse and rehospitalization.
How to Use
INVEGA SUSTENNA is a long-acting injectable suspension administered by a healthcare professional. It is not intended for self-administration.
- The initial treatment typically involves two loading doses administered one week apart.
- Subsequent maintenance doses are given once a month.
- The injection is administered intramuscularly into the deltoid or gluteal muscle.
- Adhere strictly to the dosing schedule determined by your doctor to ensure optimal effectiveness.
- Do not miss scheduled appointments for your injections.
Caution & Warnings
- INVEGA SUSTENNA is a prescription-only medication. Do not use without a doctor's consultation.
- Not approved for the treatment of dementia-related psychosis due to an increased risk of death.
- May cause serious side effects, including neuroleptic malignant syndrome (NMS), tardive dyskinesia, metabolic changes (e.g., weight gain, increased blood sugar, high cholesterol), and orthostatic hypotension.
- Patients may experience allergic reactions, including anaphylaxis. Seek immediate medical attention if you develop signs of a severe allergic reaction.
- Inform your doctor about all medical conditions, including heart problems, liver or kidney disease, seizures, diabetes, and a history of suicidal thoughts or attempts.
- Avoid driving or operating machinery until you know how INVEGA SUSTENNA affects you, as it may cause drowsiness or dizziness.
- Do not abruptly stop taking this medication without consulting your healthcare provider.
Ingredients
Active Ingredient: Paliperidone palmitate (50 mg, equivalent to 39 mg of paliperidone)
Inactive Ingredients: Polysorbate 20, polyethylene glycol 4000, citric acid monohydrate, disodium hydrogen phosphate anhydrous, sodium dihydrogen phosphate monohydrate, sodium hydroxide, water for injection.
Product Details
- Product Type: Long-acting injectable antipsychotic
- Dosage Form: Pre-filled syringe
- Strength: 50 mg
- Manufacturer: Janssen Pharmaceuticals (a Johnson & Johnson company)
- Indications: Treatment of schizophrenia and schizoaffective disorder in adults.
- Storage: Store at room temperature (25°C), away from freezing and excessive light.
| Gtin | 2411222928 |
|---|---|
| Recommended Sale Price | 646.35 |
| Is Wasfaty Product | No |
| Brand | Invega |
| Ingredient Name | PALIPERIDONE |
| SFDA Reg. No | 2411222928 |
| IBC | 2411222928 |
| Drug Type | Prescription |
| Scientific Name | Paliperidone palmitate |
| Strength | 50 mg |
| Strength Unit | mg |
| Form | Pre-filled syringe |
| Admin Route | Intramuscular |
| Size | 1 |
| Size Unit | syringe |
| Package Types | Pre-filled syringe |
| Package Size | 1 syringe |
| shelfLife | 24 months |
| Storage conditions | Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). Do not freeze. Protect from light. |
| Refrigerator Storage | No |


